Fmoc-leucine-d3

Fmoc-leucine-d3 is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1].

Product Specifications

CAS Number

[538372-74-6]

Product Name Alternative

N-FMOC-leucine-d3; NPC 15199-d3; NSC 334290-d3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PPAR

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Metabolic Disease

Purity

99.25

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])C(C)C[C@@H](C(O)=O)NC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O

Molecular Formula

C21H20D3NO4

Molecular Weight

356.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Rocchi S, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell. 2001 Oct;8 (4) :737-47.